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Abstract. 
 
Intracellular transport of newly synthesized 
and mature proteins via vesicles is controlled by a large 
group of proteins. Here we describe a ubiquitous rat 
protein—endoplasmic reticulum (ER) and Golgi 30-kD 
protein (ERG30)—which shares structural characteris-
 
tics with VAP-33, a 33-kD protein from 
 
Aplysia califor-
nica 
 
which was shown to interact with the synaptic pro-
tein VAMP. The transmembrane topology of the 30-kD 
ERG30 corresponds to a type II integral membrane 
protein, whose cytoplasmic NH
 
2 
 
terminus contains a 
predicted coiled-coil motif. We localized ERG30 to the 
ER and to pre-Golgi intermediates by biochemical and 
immunocytochemical methods. Consistent with a role 
in vesicular transport, anti-ERG30 antibodies speciﬁ-
cally inhibit intra-Golgi transport in vitro, leading to 
signiﬁcant accumulation of COPI-coated vesicles. It ap-
pears that ERG30 functions early in the secretory path-
way, probably within the Golgi and between the Golgi 
and the ER.
Key words: endoplasmic reticulum • Golgi • coated 
vesicles • secretion • transport intermediates
 
T
 
RANSPORT
 
 of proteins between different organelles
of eukaryotic cells is mediated by coated vesicles
that bud from one membrane compartment and are
targeted to and fuse with an appropriate acceptor or-
ganelle (Palade, 1975; Rothman, 1994).
Budding of vesicles is regulated by small GTPases and
mediated by cytosolic coat proteins (COP)
 
1
 
 that assemble
on the donor membrane (Rothman and Wieland, 1996;
Schekman and Orci, 1996). COPII vesicles mediate trans-
port of proteins from the ER to the Golgi apparatus (Bar-
lowe et al., 1994; Campbell and Schekman, 1997), whereas
COPI vesicles are implicated in transport through the
Golgi (Malhotra et al., 1989; Ostermann et al., 1993; Orci
et al., 1997) as well as in retrograde transport of proteins
from the Golgi back to the ER (Cosson and Letourneur,
1994; Letourneur et al., 1994; Orci et al., 1997).
Docking of vesicles to the appropriate target membrane
involves interaction between integral membrane proteins
located on the vesicle, called v-SNAREs, and the target
membrane proteins, t-SNAREs (Söllner et al., 1993b; Pfef-
fer, 1996). Before this pairing event, initial docking of a
vesicle with its specific target organelle is mediated by a
peripheral membrane protein, p115 (Nakamura et al.,
1997), originally identified as a protein needed for intra-
Golgi transport (Waters et al., 1992). P115 interacts with
two integral membrane proteins, giantin, located on COPI
vesicles, and GM130, a Golgi matrix protein, thus provid-
ing a bridge between vesicles and their target membrane
(Sonnichsen et al., 1998). In yeast, Uso1p (the homologue
of mammalian p115) acts together with the small GTPase
Ypt1p before the formation of SNARE pairs (Lupashin et
al., 1996; Sapperstein et al., 1996; Lupashin and Waters,
1997), and initiates docking of ER-derived COPII vesicles
to the Golgi (Cao et al., 1998).
Following pairing, the v/t-SNARE complex binds two
soluble factors: NEM-sensitive fusion protein (NSF) and
soluble NSF attachment protein (SNAP). These, in turn,
catalyze the disassembly of the SNARE complex (Söllner
et al., 1993a) after a round of fusion, thereby allowing a
new round of transport (Mayer et al., 1996; Otto et al.,
1997; Ungermann et al., 1998). However, the events that
lead to membrane fusion following the docking of vesicles
are still being investigated. It has been argued that the
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SNARE complex allows the cell to overcome the energy
barrier required for membrane fusion (Fasshauer et al.,
1997; Hanson et al., 1997). Furthermore, Weber et al.
(1998) used liposomes reconstituted with t- or v-SNAREs
to show that the v/t-SNARE complex per se fulfills the
minimal requirement for lipid mixing (hemi-fusion) and
possibly fusion between two membranes. Yet, Ungermann
et al. (1998), using an in vitro system that reconstitutes ho-
motypic fusion of yeast vacuoles, hypothesized that the
formation of the SNARE complex is only an intermediate
step in the overall fusion reaction. According to this view,
SNARE molecules are involved in docking and possibly in
hemi-fusion between donor and acceptor membranes, but
another set of proteins is involved in subsequent stages of
the fusion process. This notion is supported by Peters and
Mayer (1998), who suggested that calmodulin and other
yet-unidentified factors are involved in mediating late
stages of vacuolar fusion.
The vesicle-associated membrane protein (VAMP)–
associated protein of 33 kD (VAP-33) was identified in
 
Aplysia californica
 
 (Skehel et al., 1995b). This protein is
conserved in evolution with homologues found in 
 
Saccha-
romyces cerevisiae 
 
(
 
SCS2
 
) (Nikawa et al., 1995), 
 
Cae-
norhabditis
 
 
 
elegans
 
 (Klass et al., 1984), 
 
Arabidopsis
thaliana
 
 (Galaud et al., 1997), and humans (Weir et al.,
1998). Antibodies directed against VAP-33 blocked neu-
rotransmission when injected into cultured neurons, sug-
gesting that in 
 
A
 
.
 
 californica
 
 this protein is involved in
neurotransmitter release. The yeast 
 
SCS2
 
 gene has been
cloned as a suppressor of inositol auxotrophy of 
 
CSE1
 
 and
 
hac/ire
 
15 mutants (Nikawa et al., 1995) and was recently
characterized as an integral membrane protein of the ER
(Kagiwada et al., 1998). The 
 
C
 
.
 
 elegans
 
 major sperm pro-
tein, a 127–amino acid long protein, also exhibits signifi-
cant homology with the NH
 
2
 
 terminus of VAP-33. Major
sperm protein is thought to be involved in sperm pseu-
dopodial movement, by forming a cytosolic filamentous
network that translocates vesicles to the plasma mem-
brane (Italiano et al., 1996).
In the present study we describe a VAP-33–related pro-
tein which we denote ERG30, and demonstrate its type II
transmembrane topology. We found that ERG30 is local-
ized in the ER and in pre-Golgi intermediates. Functional
in vitro assays attribute to ERG30 a role in COPI vesicle
transport. We put forward the hypothesis that ERG30 is
involved in intra-Golgi transport and in retrograde trans-
port of proteins between the Golgi and the ER.
 
Materials and Methods
 
Construction of Bait Plasmids
 
ERG30 was cloned by the two-hybrid system using the cytosolic portion
of Neu differentiation factor 
 
b
 
4a (NDF
 
b
 
4a
 
290-662
 
) as a bait. NDF
 
b
 
4a
 
290-662
 
was generated by PCR with EcoRI and BamHI ends using the following
primers: 5
 
9
 
-CCGGAATTCACCAAGAAGCAGCGGCAG-3
 
9
 
 and 5
 
9
 
-
CGCGGATCCTTATACAGCAATAGGGTC-3
 
9
 
. The resulting PCR
product was digested with EcoRI and BamHI and cloned into the appro-
priate sites in the pGBT9 vector (Clontech) downstream from the GAL4
DNA binding domain. This plasmid was transformed into the two-hybrid
strain HF7c reporter strain (Clontech), and tested for expression of the fu-
sion protein by Western analysis. The inserted fragment was sequenced to
verify that no mutation had occurred because of PCR and to confirm the
correct reading frame of the resultant fusion protein.
 
Construction of a Rat Brain cDNA Library in the 
pACT Vector
 
A cDNA library was constructed from 5 
 
m
 
g of oligo (dT)-selected mRNA,
using a Stratagene kit. RNA was prepared from rat brain by the guanidin-
ium thiocyanate-phenol-chloroform extraction method. The mRNA was
purified and used as a template for cDNA synthesis. The resulting
dscDNA was methylated by XhoI methylase and ligated to an EcoRI
linker, thus generating an EcoRI site at the 5
 
9
 
 end of the cDNA and an
XhoI site at the 3
 
9
 
. The average size was 
 
z
 
2.5 kb. The purified dscDNA
was ligated to 
 
l
 
ACT. The library titer was 
 
z
 
1.4 
 
3
 
 10
 
7
 
 pfu. The titer of the
library after amplification was 3 
 
3
 
 10
 
9
 
 pfu/ml. In vivo excision was per-
formed from the phagemid 
 
l
 
ACT to pACT.
 
Two-Hybrid Screen
 
The HF7c yeast strain carrying the bait plasmid pGBT9-NDF
 
b
 
4a
 
290-662
 
was transformed with the rat brain cDNA library generated in pACT AD
vector (Clontech). Transformation efficiency was assessed by plating
small aliquots onto SCD plates lacking tryptophan, leucine, and histidine
and supplemented with 10 mM 3-AT. The yeast colonies were transferred
to nitrocellulose filters (BA85; Schleicher and Schuell), immersed in liq-
uid nitrogen for 5 s, and incubated at 30
 
8
 
C on a 3-mm Whatman paper
soaked with 60 mM Na
 
2
 
HPO
 
4
 
, 40 mM NaH
 
2
 
P0
 
4
 
, pH 7.0, 10 mM KCl, 1 mM
MgSO
 
4
 
, 50 mM 
 
b
 
-mercaptoethanol, and 1 mg/ml X-GAL. Colonies con-
taining the interacting pair of proteins became blue within 2–6 h. From an
initial screen of 200,000 colonies, we isolated 5 individual clones contain-
ing different cDNAs corresponding to the same mRNA. To isolate library
plasmids from positive clones, cells were grown in SC liquid media lacking
leucine (to allow loss of bait, but not of the library plasmid), and plasmid
DNA was prepared and transformed at low dilution into HB101 compe-
tent 
 
Escherichia coli
 
 cells. The transformants were selected on a M9 mini-
mal medium containing 50 
 
m
 
g/ml Amp. Plasmids isolated were then
used to retransform SFY526 yeast cells either alone or with pGBT9-
NDF
 
b
 
4a
 
290-662
 
.
 
 
 
Transformants were assayed for 
 
b
 
-galactosidase activity.
cDNA isolated from the positive clones was subcloned to 
 
p
 
Bluescript-II,
and then sequenced using an Applied Biosystems 373A automated DNA
sequencer and Applied Biosystems 
 
Taq
 
 Dye Deoxy™ Terminator cycle
sequencing kit. Of the five colonies isolated by this screen, clone pACT17
contained the complete coding sequence of ERG30. RT-PCR performed
on rat brain mRNA, using a specific oligonucleotide derived from
pACT17, confirmed that the sequence obtained from the cDNA library
was the full-length cDNA.
 
Construction and Expression of MBP-ERG30
Fusion Proteins
 
ERG30 and its truncated forms were tagged at their NH
 
2
 
 terminus with a
maltose binding protein (MBP) domain. For that purpose, full-length
ERG30, ERG30 (
 
D
 
coiled-coil) (amino acids 1–140), or ERG30 (
 
D
 
NH
 
2
 
terminus) (amino acids 141–243) was ligated into the EcoRI BamHI site
of pMAL-p2 vector (New England Biolabs). The different fusion proteins
were overexpressed in the JM109 strain of bacteria by growing log phase
bacteria in the presence of 1 mM IPTG for 4 h. Cell extracts were pre-
pared by sonicating the bacteria in a buffer containing 50 mM Tris (pH
8.0), 50 mM KCl, 0.1 mM EDTA, and 1% Triton X-100. Bacterial extracts
were centrifuged in a Ti60 rotor (Beckman) at 45,000 rpm for 60 min, and
the supernatant was passed over a 1-ml amylose column at 4
 
8
 
C. The col-
umn was washed with 10 column volumes of 20 mM Tris-HCl (pH 7.4),
0.4 M NaCl, and 10 mM 
 
b
 
-mercaptoethanol. The protein of interest was
eluted with the above buffer plus 10 mM maltose.
 
Production of Anti-ERG30 Antibodies
 
An antiserum was raised in rabbits against a recombinant MBP-ERG30
protein purified from 
 
E. coli
 
. The antiserum was first run through CNBr
activated Sepharose column with covalently bound MBP, to remove anti-
MBP antibodies. Anti-ERG30 antibodies were purified from the flow-
through material of the first column by affinity chromatography on a
CNBr-activated Sepharose column with covalently bound MBP-ERG30
fusion protein.
 
Subcellular Fractionation
 
Rat liver homogenates were fractionated over sucrose gradients as de-
scribed previously (Taylor et al., 1997; Walter et al., 1998), with slight 
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modifications. Fresh rat livers (25 g) were mixed with 150 ml of ice-cold
homogenization buffer (0.5 M sucrose, 0.1 M KPi, pH 6.8, 5 mM MgCl
 
2
 
,
1 mM DTT, 1 mM PMSF, 2 
 
m
 
g/ml aprotonin, 2 
 
m
 
M pepstatin A, and 0.5
 
m
 
g/ml leupeptin) and the tissue was minced and homogenized by forcing it
through a fine stainless steel mesh (aperture 150 
 
m
 
m). The homogenate
was centrifuged in a SLA-1500 rotor (Sorvall) for 10 min at 3,000 rpm.
The postnuclear supernatant was layered over a 0.86/1.25 M sucrose step
gradient. The gradients were centrifuged at 4
 
8
 
C in a SW-28 rotor (Beck-
man) at 25,000 rpm for 90 min. The 0.86/1.25 M interface was adjusted to
1.6 M sucrose and layered into SW-28 tubes. This layer was overlaid with
1.25 M, 1 M, 0.86 M, and 0.5 M sucrose solutions. The gradient was centri-
fuged at 4
 
8
 
C in a SW-28 rotor (Beckman) at 25,000 rpm for 2.5 h. The
samples were continuously collected from the top, tested for their sucrose
concentration, and subjected to Western blot analysis with different anti-
bodies.
 
Drug Treatment and Immunofluorescence Microscopy
 
NRK or CHO cells were seeded onto microscope slides 24 h before stain-
ing. For drug treatment before immunofluorescence microscopy, cells
were incubated for 1 h in RPMI (NRK cells) or in 
 
a
 
-MEM (CHO cells)
medium containing 10 
 
m
 
g/ml brefeldin A (BFA). To fix cells for micros-
copy, the growth medium was removed and cells were incubated for 10
min in methanol at 
 
2
 
20
 
8
 
C. Cell staining involved a 1-min incubation in ac-
etone at 
 
2
 
20
 
8
 
C for permeabilization followed by incubation in a blocking
solution containing 10% FCS in PBS. Cells were incubated for 2 h with
the primary antibodies in 2% FCS in PBS, then washed three times with
PBS and incubated in an incubation solution containing affinity-purified
fluorescein- or rhodamine-labeled antibodies against mouse or rabbit IgG.
Slides were finally washed three times with PBS, and mounted beneath
coverslips. The stained cells were analyzed with an MRC1024 confocal mi-
croscope (BioRad).
 
EM/Immunocytochemistry of CHO Cells
 
CHO cells were grown on glass coverslips that had been coated with car-
bon and gelatin (Olek et al., 1986). Preembedding immunogold-silver la-
beling was performed by a modification of the method described by Tan-
ner et al. (1996). Cultures were rinsed with serum-free culture medium
and fixed for 45 min in 4% paraformaldehyde, 4% sucrose, and 0.1 M so-
dium phosphate buffer, pH 7.4. The first 15 min of fixation were at room
temperature, followed by 30 min at 4
 
8
 
C. Fixed cultures were washed with
ice-cold Dulbecco’s phosphate-buffered saline (DPBS), then permeabi-
lized for 1 h at room temperature in 0.05% saponin, 10% normal goat se-
rum, and 1% BSA in DPBS. Cultures were then incubated for 1 h at room
temperature with affinity-purified antibodies to ERG30 diluted to 10 
 
m
 
g/ml
with 0.05% saponin, 1% BSA in DPBS. For controls, cultures were incu-
bated without antibodies to ERG30 or with ERG30 antibodies that had
been preabsorbed for 30 min at 36
 
8
 
C with a 50-fold molar excess of MBP-
ERG30, and centrifuged to remove any precipitate. After several washes
with the diluent, cultures were incubated for 1 h at room temperature with
1.4 nm gold-conjugated Fab
 
9
 
 fragments of goat anti–rabbit IgG (Nano-
probes) diluted 1:100, followed by washes with diluent and DPBS, and
further fixation for 40 min in 2% glutaraldehyde, 0.1 M sodium phosphate
buffer, pH 7.4. The glutaraldehyde-fixed cultures were washed several
times with DPBS, then with double-distilled water, before silver enhance-
ment under a dark-red safelight for 4–8 min performed according to in-
structions provided by Nanoprobes with their HQ silver enhancement kit.
After several washes with double-distilled water and DPBS, cultures were
treated with 0.2% OsO
 
4
 
 for 30 min at room temperature followed by en
bloc staining with uranyl acetate, dehydration, and embedding in Epon,
all as described (Olek et al., 1986). Thin sections were cut parallel to the
plane of the culture substrate and stained with uranyl acetate and lead ci-
trate. Observations were made by transmission electron microscopy on
 
.
 
100 cells from both the K1 (ATCC) and NDF-expressing CHO cell lines
(Burgess et al., 1995).
 
Cis- to Medial-Golgi Transport Assay
 
The standard assay mixture (25 
 
m
 
l) contained 0.4 
 
m
 
Ci UDP-[
 
3
 
H] N-acetyl-
glucosamine (America Radiolabeled Chemical), 5 
 
m
 
l of a 1:1 mixture of
donor and acceptor CHO Golgi membranes, and crude bovine brain cyto-
sol, as described (Balch et al., 1984).
 
Isolation of COPI Vesicles
 
Golgi-derived COPI vesicles were isolated as described previously
(Stamnes et al., 1995). In brief, Golgi membranes were isolated from wild-
type CHO cells as described and prewashed with 250 mM KCl. The mem-
branes (0.25 mg/ml) were then incubated with crude bovine brain cytosol
(16 mg/ml) in 0.5 ml transport assay buffer (see above) for 15 min at 37
 
8
 
C.
After incubation, KCl was added to a final concentration of 250 mM, and
the Golgi membranes were pelleted as above. The supernatant was mixed
with 1 ml of 70% (wt/wt) sucrose and overlayed in 5 ml SW 55 ultracen-
trifugation tubes with 0.5 ml 45% (wt/wt) sucrose, and 1 ml 40%, 35%,
and 30% (wt/wt) sucrose in 20 mM Tris, pH 7.4. The gradient was centri-
fuged for 14 h at 50,000 rpm at 4
 
8
 
C and fractionated into 7 fractions of 0.7 ml
each. The indicated fractions were diluted twofold in double distilled wa-
ter and membranes were pelleted by ultracentrifugation for 40 min at 4
 
8
 
C
in a TLA 100.1 rotor at 100,000 rpm. The membrane pellets were dis-
solved in SDS-PAGE sample buffer, after which the proteins were sepa-
rated by electrophoresis and blotted onto nitrocellulose filters. The 
 
b
 
 sub-
unit of COPI (
 
b
 
COP) was detected by Western blot analysis using
monoclonal anti-
 
b
 
COP antibodies M3A5 as described (Palmer et al.,
1993).
 
Formation of 20S Particles
 
For the isolation of 20S SNARE particles we used the procedure de-
scribed by Söllner et al. (1993b). In brief, crude rat brain membranes were
incubated with 10 mM Hepes/KOH, pH 7.8, 100 mM KCl, 2 mM MgCl
 
2
 
,
1 mM DTT, and 4% (vol/vol) Triton X-100 on ice for 45 min and the sus-
pension was clarified by ultracentrifugation for 60 min at 50,000 rpm in a
Ti-60 rotor. The supernatant was dialyzed against 100 vol of 25 mM Tris-
HCl, pH 7.8, 50 mM KCl, 1 mM DTT, 1% Triton X-100. The dialyzed ma-
terial was ultracentrifuged in a Ti-60 rotor for 60 min at 50,000 rpm. This
rat brain extract was incubated with His
 
6
 
-
 
a
 
SNAP and NSF-Myc in a buffer
containing 25 mM Hepes-HCl, pH 7.0, 75 mM KCl, 1 mM DTT, 2 mM
EDTA, 0.75% Triton X-100 and 0.5 mM ATP
 
g
 
S, 1% (wt/vol) polyethyl-
eneglycol (PEG 400), and 0.5 mM PMSF for 30 min at 4
 
8
 
C. Mouse anti-
Myc monoclonal antibodies coupled to protein G–Sepharose were added
and the incubation continued for an additional 2 h with constant agitation.
The beads were then washed with 10 vol of buffer A (25 mM Hepes-HCl,
pH 7.0, 100 mM KCl, 1 mM DTT, 2 mM EDTA, 0.5% Triton X-100, and
0.5 mM ATP
 
g
 
S), followed by elution with buffer A containing 8 mM
MgCl
 
2
 
 (nonspecific elution), or with buffer A containing 8 mM MgCl
 
2
 
 and
0.5 mM ATP to allow ATP hydrolysis (specific elution). The eluted frac-
tions were precipitated with trichloroacetic acid, boiled, and analyzed by
Western blotting using the appropriate antibodies.
 
Western Blot Analysis
 
To prepare rat tissue extracts, frozen organs were washed in cold PBS and
lysed with a homogenizer (PCU Kinematica) in ice-cold protein extrac-
tion buffer containing 0.5 M 
 
b
 
-glycerophosphate, 15 mM EGTA, 10 mM
EDTA, 1 mM ortho-vanadate, 1 mM benzamidine, 10 
 
m
 
g/ml aprotinin, 10
 
m
 
g/ml leupeptin, 2 
 
m
 
g/ml pepstatin A, and 1 mM DTT, at pH 7.4. Lysates
were cleared by 15 min spin at 20,000 rpm at 4
 
8
 
C. Supernatants were then
mixed with sample buffer and heated to 95
 
8
 
C for 2 min. Equal amounts of
tissue extracts were subjected to SDS-PAGE (15% acrylamide), trans-
ferred to nitrocellulose (Sartorius), and probed with anti-ERG30 antibod-
ies using HRP-coupled secondary antibodies and ECL reagent (Amer-
sham).
 
Immunoprecipitation
 
Rat brain membranes were isolated as described previously (Söllner et al.,
1993b), and solubilized with 4% Triton X-100 as described above. This
membrane extract was diluted 1 to 4 (vol/vol) with a buffer containing 10 mM
Hepes/KOH, pH 7.8, 100 mM KCl, 2 mM MgCl
 
2
 
, 1 mM DTT, and incu-
bated with protein A–agarose coupled to different antibodies for 2 h at
4
 
8
 
C. Immune complexes were washed five times with the immunoprecipi-
tation buffer and subjected to Western blot analysis.
 
Fractionation by Triton X-114
 
Rat liver Golgi fractions were washed once with Tris-salt buffer (10 mM
Tris-HCl, pH 7.6) and resuspended to a protein concentration of 4 mg/ml.
Triton X-114 was added at 4
 
8
 
C to a final concentration of 2% (wt/vol).
Solubilized membranes were incubated on ice for 4 min and then centri- 
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fuged for 10 min in a Beckman TLA100.1 rotor at 37,000 
 
g
 
. The superna-
tant was layered over a cushion of 0.25 M sucrose in a Tris-salt buffer con-
taining 0.06% Triton X-114, and incubated at 30
 
8
 
C for 5 min. After
centrifugation at 2,500 
 
g
 
 in a benchtop centrifuge, the Triton X-114 phase
was saved. The aqua phase was brought to 0.5% Triton X-114, and lay-
ered once more on a cushion, incubated at 30
 
8
 
C for 5 min, and centrifuged
as described before. The detergent layers were combined and the super-
natant kept separately. Before the SDS-PAGE separation the detergent
was removed by Biobeads SM-2 (Bio-Rad).
 
Results
 
Cloning cDNA Encoding ERG30
We have serendipitously cloned by the two-hybrid screen
system a cDNA from a rat brain cDNA library that en-
codes a 30-kD protein. Because our analysis indicated that
ERG30 is located in the ER and Golgi (see below), we
have tentatively termed it ERG30. The nucleotide and de-
duced amino acid sequence of the cDNA are shown in Fig.
1 A. The hydrophobicity profile of ERG30 suggests that
its COOH-terminal region is highly hydrophobic [residues
224–243 (Kyte and Doolittle, 1982)] (Fig. 1 B). In addition,
we identified a predicted coiled-coil motif at positions
161–194 (Fig. 1, A and C). The amino acid sequence of
ERG30 exhibits a high degree of homology to three inte-
gral membrane proteins: Scs2p, found in S. cerevisiae; the
VAMP-associated protein, VAP-33, of A. californica; and
the homologous hVAP-33 of humans (Nikawa et al., 1995;
Skehel et al., 1995b; Weir et al., 1998) (Fig. 1 D). Com-
pared with hVAP-33, aVAP-33, and Scs2p, ERG30 dis-
plays 62%, 52%, and 27% identity and an overall 86%,
70%, and 50% similarity, respectively.
ERG30 Is a Type II Integral Membrane Protein
The expression pattern of ERG30 in various rat tissues
was examined by immunoblot analysis using affinity-puri-
fied anti-ERG30 antibodies. As evident from Fig. 2 A, the
30-kD ERG30 protein is expressed in all tissues studied
with a smaller 28-kD isoform, or a proteolytic product in
the kidney, liver, and heart.
Because the amino-acid sequence of ERG30 suggested
that it might contain a COOH-terminal transmembrane
domain (Fig. 1 B), we examined its putative transmem-
brane topology by using anti-ERG30 antibodies for immu-
noblot analyses of cytosolic and membrane fractions. In
rat brain, ERG30 was detected almost exclusively in the
membrane fraction (Fig. 2 B). The association of ERG30
with the membrane fraction was resistant to washing with
1 M KCl (data not shown) and the protein could be ex-
tracted entirely into a detergent phase upon solubilization
with Triton X-114 (Fig. 2 B). Using an in vitro translation
system, we demonstrated that ERG30 was translocated
into the microsomal membranes (Fig. 2 C). To exclude the
possibility of peripheral association with the microsomal
membranes, the translated products were incubated with
Figure 1. (A) Nucleotide and amino acid se-
quences of ERG30. The complete primary struc-
ture and key elements of ERG30 are indicated.
The hydrophobic motif is boxed. The predicted
coiled-coil motif at positions 161–194 is regis-
tered starting in c. (B) Hydropathy profile of
ERG30 gene product. Kyte-Doolittle hydropho-
bicity profile of ERG30 indicates the position of
a hydrophobic domain from residues 223 to 238,
the putative transmembrane domain. (C) The
coiled-coil prediction of ERG30 protein. Coiled-
coil prediction was performed with the computer
algorithm PAIRCOIL using a scoring cutoff of
0.50 as positive. Maximum probability (1.0) was
found at positions 161–194. (D) Alignment of
amino acid sequence of ERG30 with related pro-
teins. The ERG30 amino acid sequence was
aligned with those of human (hVAP33), A. cali-
fornica (aVAP33), and S. cerevisiae (Scs2p). Res-
idues identical in three sequences are boxed;
shading highlights similarities between se-
quences.Soussan et al. ERG30 Participates in COPI-mediated Vesicular Transport 305
100 mM Na2CO3, pH 11. Under these conditions ERG30
remained associated with the membrane fraction (Fig. 2
C). We next addressed the topology of ERG30 with re-
spect to the cytosol by using a protease protection assay.
Treatment of the in vitro translated ERG30 (in the pres-
ence of microsomes) with proteinase K fully digested the
translated protein, whereas the mature form of E. coli
b-lactamase, serving as a control protein translocated into
the microsomes lumen, was fully protected (Fig. 2 C).
Taken together, these results indicate that ERG30 is a
type II integral membrane protein, with an NH2-terminal
domain facing the cytoplasm and a very short COOH-ter-
minal hydrophobic domain located inside the membrane
(Fig. 2 D).
Self-oligomerization of ERG30
ERG30 shares with SNAREs a similar domain organiza-
tion, including a predicted membrane-proximal coiled-coil
domain, a motif common to various self-oligomerizing
proteins involved in protein-protein interactions (Weimbs
et al., 1997). To test whether ERG30 is capable of self-oli-
gomerization we employed the yeast two-hybrid system.
Two ERG30 truncation mutants were prepared: ERG30
(DNH2 terminus) containing residues 141–243, and its com-
plementary coiled-coil deletion mutant (Dcoiled-coil) con-
taining residues 1–140. Yeast cells were cotransfected with
a construct of ERG30 fused to the Gal4 DNA binding do-
main, and ERG30 fused with pACT Gal4-activation do-
main. Only cells that contained both constructs were able
to grow on a selective medium and exhibited significant
bGal activity. Furthermore, as shown in Fig. 3, only the
full length ERG30 was able to self-oligomerize in vivo,
whereas the truncated forms, i.e., ERG30 (Dcoiled-coil) or
ERG30 (DNH2 terminus), were inactive. Our results indi-
cate that ERG30 can self-oligomerize and both the coiled-
Figure 1 (continued)
Figure 2. (A) Tissue distribution of ERG30 protein. Equal
amounts (42-mg protein) of total extracts from the indicated tis-
sues were analyzed by immunoblot with anti-ERG30 specific an-
tibodies. No differences were observed in the total amount of
protein between the different samples, as determined by amido-
black staining of the nitrocellulose filters. (B) ERG30 is an inte-
gral membrane protein. Rat brain membrane extract and cytosol
(prepared as described in Materials and Methods) were sub-
jected to immunoblot analysis with antiserum specific to ERG30.
The Golgi membranes were fractionated by Triton X-114 (see
Materials and Methods), with the aqua phase representing the
proteins found in the buffer fraction and the detergent phase pro-
teins fractionated with Triton X-114. (C) ERG30 resides on the
cytoplasmic surface of the membrane. ERG30 was translated in
vitro in the presence or absence of canine pancreatic microsomes
(in the minus microsomes experiment, microsomes were added at
the end of the translation reaction). The translation mixture was
exposed to alkaline pH and the microsomal pellet (P) and super-
natant (S) were separated by centrifugation as described in Mate-
rials and Methods. To determine the membrane topology of the
protein, ERG30 and b-lactamase were translated in vitro in the
presence of microsomes and then were incubated for 60 min with
1 mg/ml proteinase K with or without addition of Triton X-100 to
a final concentration of 1% as indicated. The proteolysis was
stopped by adding 4 mM phenylmethylsulfonyl fluoride and the
samples were analyzed on 15% SDS-PAGE. (D) Schematic rep-
resentation of ERG30 topology.The Journal of Cell Biology, Volume 146, 1999 306
coil and the NH2-terminal motifs appear indispensable for
oligomerization.
ERG30 Is Localized to the ER and the
Pre-Golgi Intermediates
Intracellular targeting of a protein to a particular or-
ganelle often provides a valuable insight into its specific
biological role. To examine the subcellular localization of
ERG30 in NRK cells, we performed indirect immunofluo-
rescence analysis using affinity-purified polyclonal anti-
ERG30 antibodies. As illustrated in Fig. 4 A (panels 2 and
4), ERG30 is localized in a juxta-nuclear crescent resem-
bling the Golgi complex and possibly in parts of the ER.
No labeling was observed when anti-ERG30 antibodies
were incubated with excess recombinant ERG30 in the
form of a MBP fusion protein (data not shown). To iden-
tify the subcellular localization of ERG30, we performed a
double labeling experiment using monoclonal antibodies
directed against bCOP, a commonly used marker for the
Golgi, together with anti-ERG30 antibodies. Using confo-
cal microscopy, we found that labeling with the anti-
ERG30 antibodies partially coincided with that of bCOP,
indicating that in NRK cells ERG30 is localized in the vi-
cinity of the Golgi complex (Fig. 4 A, panels 3 and 4).
Treating cells with the drug BFA was shown previously to
specifically disrupt the Golgi complex in vivo (Lippincott-
Schwartz et al., 1989). Here we showed that in the presence
of BFA, the labeling observed by anti-bCOP spread
throughout the cytoplasm, whereas labeling with anti-
ERG30 formed a characteristic ER pattern (Fig. 4 A, pan-
els 6 and 8). To confirm the localization of ERG30 in
ER membranes, the cells were double labeled with
monoclonal antibodies directed against protein disulfide
isomerase (PDI), an ER resident protein, and with anti-
ERG polyclonal antibodies. As shown in Fig. 4 A (panels
1 and 2), part of the labeling observed with the anti-
ERG30 antibodies coincided with that of PDI, indicating
that the two proteins might share the same compartment.
Upon treatment with BFA, the colocalization of PDI and
ERG30 increased significantly (Fig. 4 A, panels 5 and 6).
The intracellular localization of ERG30 was also deter-
mined by subcellular fractionation of bovine liver postnu-
clear supernatant on equilibrium density sucrose gradients
(Fig. 4 B). Fractions were analyzed by immunoblotting
with affinity-purified anti-ERG30 antibodies and with an-
tibodies that recognize either Gos28, a marker of the
Golgi apparatus, or PDI, an ER marker. Membranes that
were concentrated at the 0.86/1.25 interface of the first
gradient were harvested, adjusted to 1.6 M sucrose, and
loaded onto the bottom of a second gradient (Fig. 4 B).
Immunoblot analysis of the second gradient showed that
ERG30 predominantly colocalizes with PDI and to some
lesser extent with Gos28, indicating that it associates with
both Golgi and ER membranes.
ERG30 subcellular localization was further analyzed by
immunoelectron microscopy. Silver grains representing
sites of immunoreactivity for ERG30 were localized pre-
dominantly on the cytoplasmic faces of the RER and on
the outer leaflet of the nuclear membrane—both sites of
synthesis for membrane and secreted proteins (Fig. 4 C,
panel 1). Labeled cisternae of RER were found through-
out the cytoplasm. Little immunoreactivity was localized
to the Golgi apparatus. However, silver grains often were
observed on RER cisternae that were very close to the
Golgi, and on cisternae that appeared to be transitional
between RER and the cis-Golgi (Fig. 4 C, panel 2 and in-
set). Very few silver grains were seen on other structures
such as the plasma membrane, mitochondria, or the nu-
cleus. These represented nonspecific labeling since they
were not eliminated by absorption of ERG30 antibodies
with excess antigen, whereas labeling of the RER, nuclear
envelope, and RER-Golgi transitional structures was vir-
tually eliminated (data not shown). Taken together, our
results indicate that ERG30 is localized on the cytosolic
surface of the ER and on the pre-Golgi intermediates.
ERG30 Is Not Part of the Synaptic SNARE Complex
It has been demonstrated in Aplysia that VAP-33 directly
interacts with the synaptic v-SNARE, VAMP, suggesting
its involvement in docking and fusion of synaptic vesicles
(Skehel et al., 1995b). We used two approaches to examine
whether ERG30 interacts with synaptic SNAREs. First,
we used monoclonal antibodies against SNAP-25 and syn-
taxin-1 to coimmunoprecipitate ERG30 from rat brain
membrane extract. As shown in Fig. 5 A, ERG30 did not
precipitate with any of the known synaptic SNAREs.
Next, we examined whether ERG30 interacts with synap-
tic SNAREs by testing its incorporation into 20S fusion
particles (Söllner et al., 1993b). The 20S particles are
formed when detergent extracts of membranes contain-
ing SNAP receptors are mixed with SNAPs and NSF in
the presence of the nonhydrolyzable analogue of ATP,
ATPgS. The 20S fusion particle assembly reaction can
therefore be used as a cell-free read-out system to test
whether candidate proteins are SNAREs, or specifically
interact with a SNARE. The results of such a 20S particle
experiment, using rat brain membrane extract as a source
for SNAREs, are presented in Fig. 5 B. Specific (Mg-ATP)
and nonspecific elutions (Mg-ATPgS) were analyzed by
Western blots. As expected, the known synaptic mem-
brane proteins VAMP, syntaxin, and SNAP-25 assembled
into the 20S particle derived from brain membrane ex-
tract, but ERG30 did not. These results indicate that
ERG30 is not part of the synaptic SNARE complex.
Figure 3. Self-oligomerization of ERG30 detected by the two-
hybrid system. Yeast cells were cotransfected with a construct of
ERG30 fused with the Gal4 DNA binding domain, and with ei-
ther full-length ERG30, ERG30 (Dcoiled-coil) or ERG30 (DNH2
terminus), fused with pACT Gal4-activation domain. The intense
b-galactosidase staining of the yeast colonies observed on the left
panel indicates an interaction between the different ERG30 fu-
sion proteins.Soussan et al. ERG30 Participates in COPI-mediated Vesicular Transport 307
ERG30 Is Involved in Intra-Golgi Transport
The subcellular distribution of ERG30 indicates that it
might play a role early in the secretory pathway. We used
the cell-free intra-Golgi transport system (Balch et al.,
1984) to examine this possibility. Affinity-purified anti-
ERG30 antibodies specifically inhibited intra-Golgi trans-
port by up to 90% of the control in a concentration-depen-
dent manner (Fig. 6 A, open squares); neither nonrelevant
control antibodies (Fig. 6 A, open triangles) nor preim-
mune IgGs had any effect on this assay (data not shown).
Recombinant ERG30 specifically reversed the inhibition
by these antibodies (Fig. 6 C). Anti-ERG30 Fab9 frag-
ments were also found to partially inhibit transport (Fig. 6
A, open rhombuses) excluding the possibility that the inhi-
Figure 4. Localization of
ERG30 in the Golgi and ER.
(A) Indirect immunofluores-
cence microscopy of endogenous
ERG30 with and without BFA
treatment of NRK cells. Local-
ization of ERG30, PDI, or b-COP
was performed in NRK cells
with and without BFA treatment
(10  mg/ml, 1 h). PDI (1 and 5
plus BFA) and b-COP (3 and 7
plus BFA) immunoreactivity
were detected with fluorescein-
conjugated secondary antibod-
ies; ERG30 immunoreactivity
(2, 4 and 6, 8 plus BFA) was de-
tected with rhodamine-conju-
gated secondary antibodies. (B)
Determination of ERG30 local-
ization by subcellular fraction-
ation. Bovine liver postnuclear
supernatant in 0.5 M sucrose was
layered on top of a sucrose step
gradient composed of 0.86/1.25 M
sucrose layers. The gradients
were centrifuged and the inter-
faces was collected (see Materi-
als and Methods). The 0.86/1.25 M
sucrose interface was adjusted to
a 1.35 M sucrose and loaded at
the bottom of a second step gra-
dient with 1.25, 1.0, 0.86, and 0.5 M
sucrose. After centrifugation,
the different fractions were ana-
lyzed by SDS-PAGE and immu-
noblotting with affinity-purified
anti-ERG30 antibodies or with
anti-PDI or anti-Gos28 antibod-
ies. (C) Immunogold-silver lo-
calization of ERG30 in CHO
(K1) cells. (Panel 1) Most silver
grains are located on the cyto-
plasmic face of RER cisternae
(arrows). Some clusters of grains
are found on indistinct struc-
tures in the cytoplasm, probably
RER cisternae sectioned tan-
gentially (asterisks). (Panel 2)
Silver grains are often found on
the cytoplasmic face of the outer
leaflet of the nuclear envelope
(arrows), on RER cisternae
(small arrows) close to the Golgi
(G), and on structures that ap-
pear to be transitional between
the RER and the Golgi (T-arrowheads). The inset shows an area on the right hand side of the transitional zone and Golgi at twofold
higher magnification, making it easier to see two small silver grains (arrowheads). Bars, 0.5 mm.The Journal of Cell Biology, Volume 146, 1999 308
bition brought about by the antibodies resulted from anti-
body-induced aggregation of ERG30 on the membrane.
To determine the stage at which ERG30 is required, anti-
ERG30 antibodies were added at different time points af-
ter initiation of transport. As shown in Fig. 6 B, transport
was inhibited by addition of anti-ERG30 antibodies to the
assay between time 0 and 10 min, establishing the involve-
ment of ERG30 in the transport process per se rather than
in the glycosylation of the VSV-G protein (i.e., after 10-
min time points).
The involvement of ERG30 in intra-Golgi transport was
also demonstrated by using soluble recombinant MBP-
ERG30. The effect of recombinant full-length MBP-
ERG30, MBP-ERG30 (Dcoiled-coil) or MBP-ERG30
(DNH2 terminus) mutants on VSV-G transport in vitro
was therefore examined. As shown in Fig. 6 D, addition of
increasing amounts of recombinant MBP-ERG30 fusion
protein inhibited transport in vitro by nearly 90%. No
inhibition was detected in the presence of equivalent con-
centrations of MBP-ERG30-Dcoiled-coil, MBP-ERG30-
DNH2 terminus, or MBP-control. This result is in agree-
ment with the fact that only the wild-type ERG30 can
interact with the endogenous ERG30, whereas the trun-
cated proteins could not (Fig. 3 B). We therefore con-
cluded that inhibition observed in the presence of the solu-
ble MBP-ERG30 results from blocking the function of the
endogenous membranal ERG30.
Anti-ERG30 Antibodies Cause an Accumulation of 
COPI-coated Vesicles
Anti-ERG30 antibodies were used to establish the stage in
the transport pathway at which ERG30 is required. For
that purpose we used conditions that promote budding of
COPI vesicles from Golgi membranes. Under such bud-
ding reactions, Golgi membranes were incubated with
crude cytosol in the presence or absence of either GTPgS
or anti-ERG30 antibodies. The Golgi cisternae were then
pelleted at 14,000 rpm and the supernatant was fraction-
ated on a sucrose gradient to isolate the COPI-coated ves-
icles. As shown in Fig. 7, incubation of Golgi membranes
in the presence of GTPgS resulted in a significant accumu-
lation of COPI-coated vesicles. A significant quantity of
COPI vesicles also accumulated in the presence of affinity-
purified anti-ERG30 antibodies. When both GTPgS and
anti-ERG30 were present in the budding reaction, even
more COPI vesicles accumulated (data not shown). Nota-
bly, the vesicles accumulated in the presence of anti-
ERG30 antibodies appeared more homogeneous in com-
parison to those accumulated in the presence of GTPgS.
These results show that ERG30 is not involved in the bud-
ding process but rather in the consumption of these vesi-
cles. Most of the ERG30 remained associated with the
Golgi cisternae and did not migrate with the accumulated
COPI vesicles (data not shown).
Discussion
We show here that ERG30, the rat homologue of aVAP-
33, is ubiquitously expressed and is localized primarily
within the ER and the pre-Golgi intermediates. The local-
ization of ERG30 suggests that it functions early in the
secretory pathway rather than in the plasma membrane.
This is further supported by the observation that ERG30
plays a role in intra-Golgi transport in vitro. We propose
that ERG30 represents a novel integral membrane protein
family which is involved in the process of vesicle fusion
with target membranes.
Previous studies demonstrated that A. californica VAP-
33 can interact with VAMP (synaptobrevin) and that it
participates in the process of synaptic release (Skehel et
al., 1995a,b). The yeast homologue, however, was local-
Figure 5. ERG30 is not part of the synaptic SNARE complex.
(A) Immunoprecipitation of ERG30 from rat brain membrane
extract. Rat brain membrane extracts were incubated with pro-
tein A–agarose coupled to the indicated antibodies. The bound
material was subjected to Western blot analysis. IP represents
immunoprecipitation. IB represents immunoblot. (B) Formation
of synaptic 20S particles. MgCl2 represents nonspecific eluate
from complete binding reaction with NSF-Myc and Mg-ATPgS;
Mg21 ATP represents specific eluate of the same column as for
N.S. following the exchange of ATP for ATP-gS (in the presence
of EDTA) and addition of MgCl2 to allow ATP hydrolysis. Syn-
taxin, SNAP-25, VAMP, and ERG30 were detected with specific
antibodies by immunoblot analysis.Soussan et al. ERG30 Participates in COPI-mediated Vesicular Transport 309
ized to the ER and was shown to be required for inositol
metabolism (Kagiwada et al., 1998). Our data clearly dem-
onstrate that the mammalian homologue of these proteins
is localized in the ER and pre-Golgi intermediates, playing
a role in protein transport in the early secretory pathway.
We could not identify an interaction between ERG30 and
synaptic SNAREs. Our immunolabeling experiments on
neuronal cells indicate that ERG30 is localized on en-
domembranes, primarily the Golgi and the ER. No label-
ing of ERG30 was seen on or near the plasma membrane,
where most of the VAMP labeling was observed (Soussan,
L., and Z. Elazar, unpublished data). We clearly demon-
strated here that ERG30 is not part of the synaptic
SNARE complex. Our data, however, does not exclude
the possibility that ERG30 interacts weakly with VAMP,
in a manner that is not resistant to immunoprecipitation
conditions. It is also possible that mammals carry other,
yet-unidentified genes that encode VAP-33 homologues
which function at later stages of the secretory pathway.
The accumulation of COPI vesicles caused by anti-
ERG30 antibodies coupled with the localization of ERG30
both in the Golgi and ER suggest that this protein is in-
volved in transport between these organelles, possibly in
the retrograde direction. The accumulation of COPI vesi-
cles may also indicate that ERG30 is involved in regulat-
ing the uncoating of these vesicles. It is not clear why the
accumulated vesicles did not uncoat in the presence of the
anti-ERG30 antibodies. ERG30 might be involved in trig-
gering ADP-ribosylation factor (ARF)-GTPase activating
protein (GAP), an activity which, in turn, stimulates the
uncoating process. Additional experiments are needed to
determine whether uncoating of vesicles is affected by
ERG30 directly, or is coupled to the vesicles’ docking; the
Figure 6. (A) Inhibition of in-
tra-Golgi transport in vitro by
anti-ERG30 antibodies. Trans-
port activity of crude cytosol,
measured by the standard trans-
port assay (see Materials and
Methods), was tested in the
presence of the indicated con-
centrations of affinity-purified
antibodies specific for ERG30
(open squares), Fab9 fragments
of anti-ERG30 (open rhom-
buses), or anti-ErbB2 (open cir-
cles) and anti-ErbB2 Fab9 (open
triangles) as controls. The Golgi
membranes were preincubated
with the different antibodies for
30 min on ice before being trans-
ferred to a 308C bath to start the
transport reaction. The extent of
[3H]GlcNAc incorporated is ex-
pressed as the percentage of the
control level of transport in re-
actions without added antibod-
ies. (B) Temporal sensitivity
of VSV-G transport to anti-
ERG30 antibodies. At the time
points indicated, the assays were shifted to ice (open squares) or the mixtures were supplemented with 1.0 mg of anti-ERG30 antibodies
and incubated at 378C for the remaining period up to 120 min (full squares). (C) Inhibition of vesicular transport by anti-ERG30 anti-
bodies is reversed by recombinant ERG30. Bars 1 and 2 describe a standard transport reaction in the presence or absence of anti-
ERG30 antibodies (0.5 mg); bars 3 and 4 describe the same transport conditions, respectively, in the presence of antibody-neutralizing
amounts of MBP-ERG30 (1.0 mg). (D) Inhibition of vesicular transport by MBP-ERG30. Increasing concentrations of fusion proteins,
MBP-ERG30, MBP-ERG30 (Dcoiled-coil) MBP-ERG30 (DNH2 terminus), or MBP alone were added to the transport reaction. The
extent of [3H]GlcNAc incorporated is expressed as the percentage of the control level of transport with no added recombinant proteins.
Figure 7. Accumulation of Golgi-derived COPI-coated vesicles.
Golgi membranes were incubated with cytosol in the presence or
absence of GTPgS or affinity-purified anti-ERG30 antibodies.
Salt was added to a final concentration of 0.25 M KCl, Golgi was
pelleted, and the supernatant (containing the vesicles) was frac-
tionated on a sucrose gradient. Fractions corresponding to the in-
dicated sucrose concentrations were analyzed for b-COP content
by Western blotting. The bottom of the gradient where the origi-
nal material was present is not shown. Total represents z20% of
the original Golgi plus cytosol of each experiment.The Journal of Cell Biology, Volume 146, 1999 310
latter would implicate a role for ERG30 in targeting vesi-
cles to the appropriate organelle.
ERG30 is a type II integral membrane protein, most of
which is presented to the cytosol. Examining the protein
sequence by the Paircoil program revealed a strong proba-
bility for a coiled-coil domain at positions 161–194 fol-
lowed by several basic residues. This structure resembles
that of the SNARE family (Weimbs et al., 1998). We did
not yet find an interaction between ERG30 and SNARE
molecules, though we demonstrated here that ERG30 can
self-oligomerize. We also demonstrated that the recombi-
nant protein, which is capable of interacting with the en-
dogenous membrane bound pool of ERG30, blocked the
cell-free intra-Golgi transport assay possibly by inhibiting
the function of the membrane-associated ERG30. Al-
though it is not clear whether this interaction is direct or
requires another membrane protein, similar to the interac-
tions between v- and t-SNARES, the evidence presented
above implicates ERG30 in the docking and fusion ma-
chinery.
We found that ERG30 functions in the early secretory
pathway, predominantly within the ER and the Golgi
complex. Our immunoelectron microscopy studies indi-
cated that it is found mainly in the ER and in transitional
elements found between this organelle and the cis-Golgi.
These structures might represent the ER-Golgi intermedi-
ate compartment, known also as pre-Golgi intermediates
(PGIs). It has been suggested by Balch and co-workers
that ER-derived transport vesicles fuse to form vesicular-
tubular clusters (VTCs) (Bannykh et al., 1996, 1998).
These structures are the target for ER-derived COPII and
Golgi-derived COPI vesicles. Considering the functional
data presented in this study, specifically the involvement
of ERG30 in COPI vesicle transport and its subcellular lo-
calization, we speculate that in addition to its intra-Golgi
activity, ERG30 is involved in retrograde transport from
the Golgi to the ER via PGIs.
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